Olema Pharmaceuticals enters $150M ATM equity offering with TD Cowen, terminates prior Oppenheimer ATM

Olema Pharmaceuticals, Inc.

Enters ATM agreement with Cowen and Company (TD Cowen) to sell up to $150M of common stock at market prices.
TD Cowen will receive up to 3.0% commission on gross proceeds from any sales under the agreement.
Terminates prior ATM agreement with Oppenheimer & Co., under which no sales were made.
No obligation to sell any shares; ATM may be terminated at any time.
Proceeds expected for general corporate purposes; registration statement effective since May 2022.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Olema Pharmaceuticals, Inc. entered into ATM Agreement with Cowen and Company, LLC valued at up to $150 million (effective 2024-01-05).

Action: entry
Agreement: atm program
Counterparty: Cowen and Company, LLC
Value: up to $150 million
Effective: 2024-01-05

Exact text from the filing

On January 5, 2024, Olema Pharmaceuticals, Inc., or the Company, entered into a sales agreement, or the ATM Agreement, with Cowen and Company, LLC, or TD Cowen, as sales agent, pursuant to which the Company may offer and sell, from time to time through TD Cowen, at its option, shares of its common stock, par value $0.0001 per share, or the Shares, having an aggregate offering price of up to $150 million.

View on SEC.gov

622 material agreements filed in the last 30 days. Browse all material agreements →

Olema Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-002543

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.